NASDAQ · PTCT
PTC Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for PTCT has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $0.02 | $0.51 | $-0.78 | 4 |
| Mar 2027 | $0.07 | $0.35 | $-0.20 | 2 |
| Jun 2027 | $0.16 | $0.38 | $-0.05 | 2 |
| Sep 2027 | $0.22 | $0.35 | $0.09 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews · MarketBeat- Fintel · Oct 30, 1:38 AM EDTPTC Therapeutics, Inc. Reports Q3 2026 Total Revenue of $358 million and Raises Full-Year GuidancePTC Therapeutics, Inc. reported total revenue of $358 million for the third quarter of 2026, including $276 million of product revenue. Sephience generated Q3 2026 revenue of $182 million, which includes $145 million revenue in the US and $37 million revenue ex-US. The company re
- Zacks · Oct 29, 5:00 PM EDTPTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Oct 29, 4:35 PM EDTPTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass EstimatesPTC Therapeutics (PTCT) delivered earnings and revenue surprises of +258.82% and +15.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 26, 9:00 AM EDTLiquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 22, 9:00 AM EDTAnalysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out forPTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Sep 25, 10:53 AM EDTWeekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) – Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across oncology, metabolic diseases, immunology and rare diseases.
- RTTNews · Sep 22, 2:32 AM EDTPTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4(RTTNews) – PTC Therapeutics, Inc. (PTCT) announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920, an investigational BLA-stage AAV gene therapy for Fabry disease.
- Zacks · Sep 18, 3:41 AM EDTImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Aug 24, 12:53 PM EDTKROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays WeakKeros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
- Zacks · Aug 24, 12:51 PM EDTShould You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
- MarketBeat · Aug 16, 11:01 AM EDTPTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction DealPTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulat
- RTTNews · Aug 13, 3:52 AM EDTPTC Expands Rare Disease Portfolio With ST-920 Acquisition(RTTNews) – PTC Therapeutics, Inc., (PTCT) has agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease from Sangamo Therapeutics in a $111 million upfront deal plus milestone payments.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for PTC Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.